https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Abemaciclib Plus Endocrine Therapy Improves Survival in Patients With HR+/HER2– Breast Cancer

Abemaciclib Plus Endocrine Therapy Improves Survival in Patients With HR+/HER2– Breast Cancer

Abemaciclib enhances overall survival in high-risk HR+, HER2– early breast cancer, establishing its role as a standard adjuvant therapy.

administrator

Related Articles